LENSAR (LNSR) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary
Event summary combining transcript, slides, and related documents.
H.C. Wainwright 26th Annual Global Investment Conference 2024 summary
21 Jan, 2026Market opportunity and technology leadership
Estimated 32 million cataract procedures in 2024, but only 1 million use laser-assisted methods.
ALLY system combines advanced imaging and dual-pulse laser for single-step, sterile procedures.
ALLY is the first to use AI with iris registration for astigmatism correction.
80 ALLY systems placed as of June 30, 2024, with 17 more pending installation.
Regulatory approvals and first shipments completed in the EU and Southeast Asia.
Efficiency, workflow, and clinical outcomes
ALLY offers the fastest laser-assisted cataract procedure, saving significant time for surgeons and staff.
Smallest footprint, wireless integration, and enhanced workflow reduce staff interactions and errors.
AI-driven astigmatism management eliminates manual data entry and improves outcomes.
Proprietary imaging ensures precise lens positioning and faster visual recovery.
Superior outcomes: 98% of patients within half a diopter of target, over 95% for arcuate incisions.
Financial impact and business value
ALLY drives $400,000–$500,000 in annual cost savings for ASCs and up to $500,000 in additional revenue per surgeon.
Saves 90–120 minutes per surgery day, enabling more procedures and higher profitability.
ALLY users saw a fivefold increase in conversion rates and $750,000 in added revenue over eight months.
44.3% gain in U.S. procedure market share since ALLY's launch.
16% increase in U.S. and 19% worldwide procedure volume in Q2 2022 vs. 2023.
Latest events from LENSAR
- Recurring revenue rose 15% in 2025, with ALLY installations up 48% and net loss sharply reduced.LNSR
Q4 202531 Mar 2026 - Record Q2 revenue and ALLY placements, global expansion, and break-even adjusted EBITDA.LNSR
Q2 20242 Feb 2026 - Q3 revenue up 38% to $13.5M, with ALLY growth and ongoing supply chain risks.LNSR
Q3 202416 Jan 2026 - Record revenue and ALLY placements in 2024 set up for faster growth and profitability in 2025.LNSR
Q4 202426 Dec 2025 - Stockholders to vote on a merger with $14.00 cash per share plus $2.75 CVR; Board recommends approval.LNSR
Proxy Filing2 Dec 2025 - Shareholders to vote on merger with Alcon, offering $14.00 per share plus $2.75 CVR.LNSR
Proxy Filing2 Dec 2025 - Shareholders to receive $14.00 per share plus a $2.75 CVR in a board-approved merger.LNSR
Proxy Filing2 Dec 2025 - Pending merger with Alcon faces regulatory review and awaits shareholder approval.LNSR
Proxy Filing2 Dec 2025 - Merger with Alcon advances, with shareholder meeting set and supplemental disclosures issued.LNSR
Proxy Filing2 Dec 2025